Evidence map›Paper›PMID 36881249›Full record

ArticleTissue engineering and regenerative medicine2023

Preclinical Evaluation of an Everolimus-Eluting Bioresorbable Vascular Scaffold Via a Long-Term Rabbit Iliac Artery Model.

Dae Sung Park, Myung Ho Jeong, Yu Jeong Jin, Mi Hyang Na, Doo Sun Sim, Munki Kim, Kyung Hoon Cho, Dae Young Hyun, Seok Oh, Jeong Ha Kim and 7 more

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering and regenerative medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Dae Sung ParkThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.ORCID 0000-0002-9948-7546
Myung Ho JeongThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea. myungho@chollian.net.
Yu Jeong JinThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Mi Hyang NaThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Doo Sun SimThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Munki KimThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Kyung Hoon ChoThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Dae Young HyunThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Seok OhThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Jeong Ha KimThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Kyung Seob LimThe Futuristic Animal Research Center, The Korean Research Institute of Bioscience and Biotechnology, Ochang, 28116, Republic of Korea.
Jun-Kyu ParkCGBio Co. Ltd., Seoul, Republic of Korea.
Han Ki KimCGBio Co. Ltd., Seoul, Republic of Korea.
Young Joon HongThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Ju Han KimThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Youngkeun AhnThe Korean Cardiovascular Stent Research Institute, Jangsung, 57248, Republic of Korea.
Jeong Hun KimDepartment of Cardiology, Chonnam National University Hospital, Gwangju, 61469, Republic of Korea.
Ministry of Health and Welfare · KRJangsung (South Korea) · KRChonnam National University · KRChonnam National University Hospital · KRKorea Research Institute of Bioscience and Biotechnology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiodegradable poly (l-lactic acid) (PLLA), a bio safe polymer with a large elastic modulus, is widely used in biodegradable medical devices. However, because of its poor mechanical properties, a PLLA strut must be made twice as thick as a metal strut for adequate blood vessel support. Therefore, the mechanical properties of a drug-eluting metal-based stents (MBS) and a bioresorbable vascular scaffolds (BVS) were evaluated and their safety and efficacy were examined via a long-term rabbit iliac artery model.

methodsThe surface morphologies of the MBSs and BVSs were investigated via optical and scanning electron microscopy. An everolimus-eluting (EE) BVS or an EE-MBS was implanted into rabbit iliac arteries at a 1.1:1 stent-to-artery ratio. Twelve months afterward, stented iliac arteries from each group were analyzed via X-ray angiography, optical coherence tomography (OCT), and histopathologic evaluation.

resultsSurface morphology analysis of the EE coating on the MBS confirmed that it was uniform and very thin (4.7 μm). Comparison of the mechanical properties of the EE-MBS and EE-BVS showed that the latter outperformed the former in all aspects (radial force (2.75 vs. 0.162 N/mm), foreshortening (0.24% vs. 1.9%), flexibility (0.52 vs. 0.19 N), and recoil (3.2% vs. 6.3%). At all time points, the percent area restenosis was increased in the EE-BVS group compared to the EE-MBS group. The OCT and histopathological analyses indicate no significant changes in strut thickness.

conclusionBVSs with thinner struts and shorter resorption times should be developed. A comparable long-term safety/efficacy evaluation after complete absorption of BVSs should be conducted.

Indexed as

Drug-Eluting StentsEverolimusAbsorbable ImplantsAnimalsCoronary AngiographyIliac ArteryRabbitsEverolimusBioresorbable vascular scaffoldDrug-eluting stentRabbit iliac artery modelSafetyStrut thickness

Identifiers

PMID36881249
PMCPMC10070568
OpenAlexW4323347252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.